Comparison of Contrast Effect on the Cochlear Perilymph after Intratympanic and Intravenous Gadolinium Injection

References

1. 1.↵
   1. Melhem ER,
   2. Jara H,
   3. Eustace S

   . Fluid-attenuated inversion recovery MR imaging: identification of protein concentration threshold for CSF hyperintensity. AJR Am J Roentgenol 1997;169: 859–62

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Mishra AM,
   2. Reddy SJ,
   3. Husain M,
   4. et al

   . Comparison of the magnetization transfer ratio and fluid-attenuated inversion recovery imaging signal intensity in differentiation of various cystic intracranial mass lesions and its correlation with biological parameters. J Magn Reson Imaging 2006;24: 52–56

   CrossRefPubMed
3. 3.↵
   1. Naganawa S,
   2. Koshikawa T,
   3. Nakamura T,
   4. et al

   . Comparison of flow artifacts between 2D-FLAIR and 3D-FLAIR sequences at 3T. Eur Radiol 2004;14: 1901–08

   PubMed
4. 4.↵
   1. Sugiura M,
   2. Naganawa S,
   3. Sato E,
   4. et al

   . Visualization of a high protein concentration in the cochlea of a patient with a large endolymphatic duct and sac, using three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging. J Laryngol Otol 2006;120: 1084–86

   PubMed
5. 5.↵
   1. Sugiura M,
   2. Naganawa S,
   3. Teranishi M,
   4. et al

   . Inner ear hemorrhage in systemic lupus erythematosus. Laryngoscope 2006;116: 826–28

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Otake H,
   2. Sugiura M,
   3. Naganawa S,
   4. et al

   . 3D-FLAIR magnetic resonance imaging in the evaluation of mumps deafness. Int J Pediatr Otorhinolaryngol 2006;70: 2115–17

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Sugiura M,
   2. Naganawa S,
   3. Teranishi M,
   4. et al

   . Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging findings in patients with sudden sensorineural hearing loss. Laryngoscope 2006;116: 1451–54

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Sone M,
   2. Mizuno T,
   3. Sugiura M,
   4. et al

   . Three-dimensional fluid-attenuated inversion recovery magnetic resonance imaging investigation of inner ear disturbances in cases of middle ear cholesteatoma with labyrinthine fistula. Otol Neurotol 2007;28: 1029–33

   CrossRefPubMed
9. 9.↵
   1. Sugiura M,
   2. Naganawa S,
   3. Sone M,
   4. et al

   . Three-dimensional fluid attenuated inversion recovery magnetic resonance imaging findings in a patient with cochlear otosclerosis. Auris Nasus Larynx 2008;35: 269–72

   CrossRefPubMed
10. 10.↵
    1. Yamazaki M,
    2. Naganawa S,
    3. Kawai H,
    4. et al

    . Increased signal intensity of the cochlea on pre- and post-contrast enhanced 3D-FLAIR in patients with vestibular schwannoma. Neuroradiology 2009;51: 855–63

    CrossRefPubMed
11. 11.↵
    1. Nakashima T,
    2. Naganawa S,
    3. Sugiura M,
    4. et al

    . Visualization of endolymphatic hydrops in patients with Ménière's disease. Laryngoscope 2007;117: 415–20

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Naganawa S,
    2. Sugiura M,
    3. Kawamura M,
    4. et al

    . Imaging of endolymphatic and perilymphatic fluid at 3T after intratympanic administration of gadolinium-diethylene-triamine pentaacetic acid. AJNR Am J Neuroradiol 2008;29: 724–26. Epub 2008 Jan 9

    Abstract/FREE Full Text
13. 13.↵
    1. Naganawa S,
    2. Satake H,
    3. Iwano S,
    4. et al

    . Imaging endolymphatic hydrops at 3 Tesla using 3D-FLAIR with intratympanic Gd-DTPA administration. Magn Reson Med Sci 2008;7: 85–91

    CrossRefPubMed
14. 14.↵
    1. Teranishi M,
    2. Naganawa S,
    3. Katayama N,
    4. et al

    . Image evaluation of endolymphatic space in fluctuating hearing loss without vertigo. Eur Arch Otorhinolaryngol 2009;266: 1871–77

    CrossRefPubMed
15. 15.↵
    1. Yamazaki M,
    2. Naganawa S,
    3. Kawai H,
    4. et al

    . Signal alteration of the cochlear perilymph on 3 different sequences after intratympanic Gd-DTPA administration at 3 Tesla: comparison of 3D-FLAIR, 3D-T1-weighted imaging, and 3D-CISS. Magn Reson Med Sci 2010;9: 65–71

    CrossRefPubMed
16. 16.↵
    1. Nakashima T,
    2. Naganawa S,
    3. Teranishi M,
    4. et al

    . Endolymphatic hydrops revealed by intravenous gadolinium injection in patients with Ménière's disease. Acta Otolaryngol 2010;130: 338–43

    CrossRefPubMed
17. 17.↵
    1. Tagaya M,
    2. Teranishi M,
    3. Naganawa S,
    4. et al

    . 3 Tesla magnetic resonance imaging obtained 4 hours after intravenous gadolinium injection in patients with sudden deafness. Acta Otolaryngol 2010;130: 665–69

    CrossRefPubMed
18. 18.↵
    1. Schwaber MK

    . Transtympanic gentamicin perfusion for the treatment of Ménière's disease. Otolaryngol Clin North Am 2002;35: 287–95

    CrossRefPubMed
19. 19.↵
    1. De Stefano A,
    2. Dispenza F,
    3. De Donato G,
    4. et al

    . Intratympanic gentamicin: a 1-day protocol treatment for unilateral Ménière's disease. Am J Otolaryngol 2007;28: 289–93

    CrossRefPubMed
20. 20.↵
    1. Haynes DS,
    2. O'Malley M,
    3. Cohen S,
    4. et al

    . Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007;117: 3–15

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Ahn JH,
    2. Han MW,
    3. Kim JH,
    4. et al

    . Therapeutic effectiveness over time of intratympanic dexamethasone as salvage treatment of sudden deafness. Acta Otolaryngol 2008;128: 128–31

    CrossRefPubMed
22. 22.↵
    1. Naganawa S,
    2. Komada T,
    3. Fukatsu H,
    4. et al

    . Observation of contrast enhancement in the cochlear fluid space of healthy subjects using a 3D-FLAIR sequence at 3 Tesla. Eur Radiol 2006;16: 733–37

    CrossRefPubMed
23. 23.↵
    1. Zou J,
    2. Poe D,
    3. Bjelke B,
    4. et al

    . Visualization of inner ear disorders with MRI in vivo: from animal models to human application. Acta Otolaryngol Suppl 2009;560: 22–31

    PubMed
24. 24.↵
    1. Naganawa S,
    2. Ishihara S,
    3. Iwano S,
    4. et al

    . Estimation of gadolinium-induced T1-shortening with measurement of simple signal intensity ratio between the cochlea and brain parenchyma on 3D-FLAIR: correlation with T1 measurement by TI scout sequence. Magn Reson Med Sci 2010;9: 17–22

    CrossRefPubMed
25. 25.↵
    1. Yoshioka M,
    2. Naganawa S,
    3. Sone M,
    4. et al

    . Individual differences in the permeability of the round window: evaluating the movement of intratympanic gadolinium into the inner ear. Otol Neurotol 2009;30: 645–48

    CrossRefPubMed
26. 26.↵
    1. Naganawa S,
    2. Kawai H,
    3. Sone M,
    4. et al

    . Increased sensitivity to low concentration gadolinium contrast by optimized heavily T2-weighted 3D-FLAIR to visualize endolymphatic space. Magn Reson Med Sci 2010;9: 73–80

    CrossRefPubMed
27. 27.↵
    1. Tagaya M,
    2. Yamazaki M,
    3. Teranishi M,
    4. et al

    . Endolymphatic hydrops and blood-labyrinth barrier in Ménière's disease. Acta Otolaryngol 2011;131: 474–79

    CrossRefPubMed
28. 28.↵
    1. Kakigi A,
    2. Nishimura M,
    3. Takeda T,
    4. et al

    . Effects of gadolinium injected into the middle ear on the stria vascularis. Acta Otolaryngol 2008;128: 841–45

    CrossRefPubMed
29. 29.↵
    1. Fukuoka H,
    2. Tsukada K,
    3. Miyagawa M,
    4. et al

    . Semi-quantitative evaluation of endolymphatic hydrops by bilateral intratympanic gadolinium-based contrast agent (GBCA) administration with MRI for Meniere's disease. Acta Otolaryngol 2010;130: 10–16

    CrossRefPubMed
30. 30.↵
    1. Fiorino F,
    2. Pizzini FB,
    3. Beltramello A,
    4. et al

    . MRI performed after intratympanic gadolinium administration in patients with Ménière's disease: correlation with symptoms and signs. Eur Arch Otorhinolaryngol 2011;268: 181–87

    CrossRefPubMed
31. 31.↵
    1. Horii A,
    2. Osaki Y,
    3. Kitahara T,
    4. et al

    . Endolymphatic hydrops in Meniere's disease detected by MRI after intratympanic administration of gadolinium: comparison with sudden deafness. Acta Otolaryngol 2011;131: 602–09. Epub 2011 Feb 23

    CrossRefPubMed